2024 - A Collaborative Approach to Advancing Access and Equity in Rare Disease Clinical Trials
Date2024-02-29
Deadline2024-02-29
VenueONLINE-VIRTUAL, USA - United States
KeywordsLife Sciences; Clinical Trials; Patient Recruitment & Retention
Topics/Call fo Papers
Ensuring that all patients have equal access to participate in clinical trials across all geographies has become essential throughout the industry. Patient recruitment and retention remain one of the most challenging hurdles in clinical development, particularly for rare diseases. Implementing a patient-focused clinical trial design and fostering a collaborative approach between the Sponsor, CRO, sites, and advocacy groups can help lead to successful clinical trials.
Given the daily obstacles faced by patients with rare diseases, including late onset Pompe disease, it is critical to minimize patient burden while recruiting a committed group of patients. Once recruited into a clinical study, it becomes paramount to provide ongoing support by focusing on the needs and concerns of the patient. This enhances patient retention, facilitating the collection of vital data for primary endpoints, which ultimately leads to faster therapies to market to give the patient community a treatment option.
In this webinar, Medpace, a global full-service CRO, will discuss the importance of equity in patient-friendly rare disease trials. Experts will discuss strategies in creating a positive clinical trial experience through a collaborative approach between sites, the Sponsor, and the CRO.
Register now for the Rare Disease Day 2024 webinar to join the discussion with clinical trial experts on a collaborative approach to patient-friendly trials in rare disease.
Keywords: Rare Disease, Drug Development, Clinical Research, CRO, Patient Recruitment, Rare Diseases, Therapeutic Areas, Rare Disease Trials, Patient Access, Patient Participation, Rare Disease Clinical Trials, Clinical Trial Access, Rare Diseases/Orphan Drugs
Given the daily obstacles faced by patients with rare diseases, including late onset Pompe disease, it is critical to minimize patient burden while recruiting a committed group of patients. Once recruited into a clinical study, it becomes paramount to provide ongoing support by focusing on the needs and concerns of the patient. This enhances patient retention, facilitating the collection of vital data for primary endpoints, which ultimately leads to faster therapies to market to give the patient community a treatment option.
In this webinar, Medpace, a global full-service CRO, will discuss the importance of equity in patient-friendly rare disease trials. Experts will discuss strategies in creating a positive clinical trial experience through a collaborative approach between sites, the Sponsor, and the CRO.
Register now for the Rare Disease Day 2024 webinar to join the discussion with clinical trial experts on a collaborative approach to patient-friendly trials in rare disease.
Keywords: Rare Disease, Drug Development, Clinical Research, CRO, Patient Recruitment, Rare Diseases, Therapeutic Areas, Rare Disease Trials, Patient Access, Patient Participation, Rare Disease Clinical Trials, Clinical Trial Access, Rare Diseases/Orphan Drugs
Other CFPs
- Updates on Human Abuse Potential Studies: Challenges and Regulatory Guidelines
- Synthesizing and Decoding Posttranslational Modifications of Disordered Proteins
- Upstream Bioprocessing: DoE Optimization for CHO Cell Cultures
- Fry Shortening Reduction Innovation and Bakery Savings
- Endpoint Protection in Rare Disease Trials: Safeguarding Data Integrity for Reliable Outcomes
Last modified: 2024-01-30 07:36:38